- Tevogen Bio (TVGN) partners with Databricks to advance precision immunotherapy AI.
- The collaboration focuses on developing machine learning models for predicting T cell receptor bindings.
- This partnership builds upon Tevogen.AI, alongside contributions from Microsoft Research.
Tevogen Bio Holdings Inc. (TVGN) has enlisted Databricks, a leader in data, analytics, and artificial intelligence (AI), to accelerate the development of PredicTcell, a proprietary AI-driven model aimed at enhancing precision immunotherapy. The collaboration will capitalize on Databricks' expertise in data engineering and AI systems to improve PredicTcell's capability in modeling immunologically active HLA+ peptide complexes and predicting T cell receptor (TCR) engagement.
This strategic partnership will concentrate on building two foundational models based on Tevogen's ExacTcell™ platform: the prediction of immunologically active peptides using machine learning and the creation of a predictive T cell receptor binding model. As part of the broader Tevogen.AI initiative, this move represents the third pillar of the company's AI strategy.
The previous pillars include significant contributions from Microsoft Research, which offers digital infrastructure and AI expertise, while Tevogen Bio itself provides clinical and immunological science leadership. This multi-faceted approach illustrates Tevogen's commitment to harnessing cutting-edge technology to transform precision medicine.
Tevogen Bio is dedicated to offering innovative healthcare solutions for large populations, with a focus on expanding access to essential medicines and advancing precision T cell therapies. The company's comprehensive strategy involves leveraging artificial intelligence to expedite drug discovery and optimize healthcare delivery.
